Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (151-160 of 219) with videos related to

Pageof 22
Sort By:
Journal of the American Academy of Dermatology|February 23, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension studyKim A Papp, James G Krueger, Steven R Feldman, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Pediatric Dermatology|March 23, 2023
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 studyLawrence F Eichenfield, Linda Stein Gold, Leon H Kircik, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.
Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Pageof 22

Showing results (151-160 of 219) with videos related to

Sort By:
Pageof 22
Journal of the American Academy of Dermatology|February 23, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension studyKim A Papp, James G Krueger, Steven R Feldman, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Pediatric Dermatology|March 23, 2023
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 studyLawrence F Eichenfield, Linda Stein Gold, Leon H Kircik, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.
Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Pageof 22